康涅狄格州吉尔福德——Hyperfine, Inc. (NASDAQ:HYPR)的首席运营官Thomas Teisseyre最近出售了2,800股公司A类普通股。这些股票以每股$0.85的价格售出，交易总额为$2,380。此次出售是为了支付与2022年3月和4月授予的限制性股票单位归属相关的预扣税义务。在此次交易之后，Teisseyre仍持有88,227股Hyperfine股票。

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared ...

Hyperfine(HYPR)发布Q3财报，2024财年前三财季累计收入1056.90万美元，去年同期累计收入为834.60万美元，同比增长26.64%。 2024财年前三财季累计净亏损3033.00万美元，去年同期累计净亏损为3355.40万美元，同比缩小9.61%。 本财年累计基本每股收益为-0.42美元，去年同期为-0.47美元。 公司所属行业为医疗保健设备。 Hyperfine, Inc.

Today’s presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the value of ultra-low-field MRI in monitoring amyloid-related imaging abnormalities (ARIA).

CE approval of the latest generation Swoop® system software is a significant milestone in Hyperfine’s international strategy, allowing broader European commercial expansion. Hyperfine secured ...

Good afternoon. And welcome to Hyperfine's Third Quarter 2024 Earnings Conference Call. Currently, all participants are in listen only mode. We will be facilitating a question-and-answer session ...

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop ...

Hyperfine (HYPR) announced CE approval of its latest generation of AI-powered Swoop system software under the European Medical Device Regulation. This approval marks a step in positioning ...

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...